Alkeon Capital Management LLC Caribou Biosciences, Inc. Transaction History

Alkeon Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$4.82 - $8.26 $1.78 Million - $3.06 Million	-370,059 Reduced 11.89%	2,743,505 $14.1 Million
Q4 2023 Feb 13, 2024	BUY	$3.58 - $6.25 $5.26 Million - $9.18 Million	1,468,701 Added 89.29%	3,113,564 $17.8 Million
Q3 2023 Nov 13, 2023	BUY	$4.08 - $8.14 $1.17 Million - $2.34 Million	287,800 Added 21.21%	1,644,863 $7.86 Million
Q2 2023 Aug 11, 2023	BUY	$4.04 - $5.47 $1.22 Million - $1.65 Million	302,418 Added 28.67%	1,357,063 $5.77 Million
Q1 2023 May 12, 2023	SELL	$4.3 - $7.78 $17,019 - $30,793	-3,958 Reduced 0.37%	1,054,645 $5.6 Million
Q4 2022 Feb 13, 2023	SELL	$5.57 - $11.01 $910,628 - $1.8 Million	-163,488 Reduced 13.38%	1,058,603 $6.65 Million
Q3 2022 Nov 10, 2022	BUY	$5.34 - $12.79 $1.86 Million - $4.46 Million	348,542 Added 39.9%	1,222,091 $12.9 Million
Q2 2022 Aug 15, 2022	SELL	$5.1 - $9.74 $1.78 Million - $3.41 Million	-350,000 Reduced 28.61%	873,549 $4.74 Million
Q1 2022 May 16, 2022	SELL	$8.42 - $15.32 $194,299 - $353,524	-23,076 Reduced 1.85%	1,223,549 $11.2 Million
Q3 2021 Nov 15, 2021	BUY	$15.75 - $30.29 $19.6 Million - $37.8 Million	1,246,625 New	1,246,625 $29.8 Million

135

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $110M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Alkeon Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alkeon Capital Management LLC with notifications on news.